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Inorganic polyphosphate [poly(P)] is a biopolymer existing in almost all cells and tissues, although its biological 
functions in higher eukaryotes have not been completely elucidated. We previously demonstrated that poly(P) 
enhances the function of fibroblast growth factors (FGFs) by stabilizing them and strengthening the affinity 
between FGFs and their cell surface receptors. Since FGFs play crucial roles in bone regeneration, we further 
investigated the effect of poly(P) on the cell differentiation of human stem cells via FGF signaling systems. 
Human dental pulp cells (HDPCs) isolated from human dental pulp show the characteristics of multipotent 
mesenchymal stem cells (MSCs). HDPCs secreted FGFs and the proliferation of HDPCs was shown to be 
enhanced by treatment with poly(P). Cell surface receptor-bound FGF-2 was stably maintained for more than 40 
hours in the presence of poly(P). The phosphorylation of ERK1/2 was also enhanced by poly(P). The effect of 
poly(P) on the osteogenic differentiation of HDPCs and human MSCs (hMSCs) were also investigated. After 5 
days of treatment with poly(P), type-I collagen expression of both cell types was enhanced. The C-terminal 
peptide of type-I collagen was also released at higher levels in poly(P)-treated HDPCs. Microarray analysis 
showed that expression of matrix metalloproteinase-1 (MMP1), osteopontin (OPN), osteocalcin (OC) and 
osteoprotegerin was induced in both cell types by poly(P). Furthermore, induced expression of MMP1, OPN and 
OC genes in both cells was confirmed by real-time PCR. Calcification of both cell types was clearly observed by 
alizarin red staining following treatment with poly(P). The results suggest that the activation of the FGF 
signaling pathway by poly(P) induces both proliferation and mineralization of stem cells. 
Key words: inorganic polyphosphate, FGF, osteogenic differentiation, cell calcification, mesenchymal stem cell, dental pulp 
cell 
1.  Introduction 
Inorganic polyphosphate [poly(P)] is a widely 
used material in food additives and cosmetics. 
Although poly(P) has also been found as a biopolymer 
in a wide range of organisms, including most 
prokaryotes and eukaryotes, and in the tissues of 
higher plants and animals [1-7], little research has 
been done in higher forms to elucidate the 
physiological functions of poly(P). 
The biological functions of poly(P) have been 
investigated primarily in microorganisms, and there 
have been only a few reports on its functions in 
eukaryotes. We previously reported that poly(P) 
enhanced the proliferation of human fibroblasts, both 
by stabilizing fibroblast growth factors (FGF-1 and 
FGF-2) and by enhancing the affinity between FGFs 
and their cell surface receptors [8]. In an in vitro study 
using osteoblast-like MC3T3-E1 cells, we revealed that 
poly(P) induces the expression of markers of bone 
differentiation and cell calcification [9]. We have also 
shown that poly(P) can accelerate periodontal tissue 
regeneration, including alveolar bone formation, in 
rats that have artificial defects in periodontal tissue 
[10].  
Many in vivo studies have shown that FGF-2 is a 
potent inducer of bone regeneration [11-13]. However, 
the in vitro effect of FGF-2 on cell mineralization is still 
obscure. Some studies have shown that an FGF-2 
inhibits collagen and alkaline phosphatase production 
and the mineralization of osteoblasts when the cells 
were continuously stimulated by FGF-2 [14-16]. On 
the other hand, it has been shown that FGF-2 
accelerates the mineralization of osteoblasts and 
multipotent stem cells (MSCs) when those cells were 
exposed to the FGF only during the late stage of cell 
mineralization [17-19]. In addition, it has been 
demonstrated that the dexamethasone-dependent 
osteogenic differentiation of MSCs is induced by 
FGF-2 and that combined treatment with FGF-2 and 
BMP-2 synergistically enhanced the osteogenic 
potency of FGF-2 in MSC cultures [20]. Although Int. J. Biol. Sci. 2008, 4 
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FGF-2 could have a basic potential to induce cell 
mineralization, it may be difficult to reproduce the 
prominent in vivo effect of FGF-2 in vitro. 
It has recently been reported that human dental 
pulp contains multipotent MSCs that have the 
potential to differentiate into odontoblasts, adipocytes 
and neuronal cells [21,22]. In order to examine the 
effect of poly(P) on the differentiation of MSCs, we 
isolated human dental pulp cells, HDPCs, which have 
the defining characteristics of MSCs. If poly(P) is 
shown to accelerate the calcification of HDPCs, 
poly(P) may be useful as an inducer for dentin 
formation. Also, since FGFs play crucial roles in bone 
regeneration as well as in soft tissue repair [11-13], it is 
reasonable to assume that poly(P) is an accelerator of 
the differentiation of MSCs to bone through the 
stabilization of FGFs. Since poly(P) is a safe material 
with very low toxicity, it could be easily applied for 
medical use as a biodegradable material.   
In this study, we examined the effect of poly(P) 
on the proliferation and differentiation of MSCs via 
activation of the FGF signaling pathway. 
2.  Materials and Methods 
Materials 
Human mesenchymal stem cells (hMSCs) and 
their growth medium (MSCBM BulletKit) were 
purchased from Cambrex Bio Science Walkersville. 
Eagle’s minimum essential medium alpha 
modification (α-MEM) and fetal bovine serum (FBS) 
were obtained from Sigma. Unless otherwise 
indicated, α-MEM used in the experiments contained 
50 μg/ml kanamycin and 0.292 mg/ml L-glutamine. 
Poly(P) having an average chain length of 60 
phosphate residues was prepared and its 
characteristics (molecular weight and its distribution) 
were determined by gel electrophoresis as previously 
described [9]. Poly(P) concentrations are represented 
in terms of phosphate residues. A Human 
Mesenchymal Stem Cell Functional Identification Kit 
(hMSC-FI kit), anti-human FGF-2 antibody and 
recombinant human FGF basic (FGF-2) were 
purchased from R & D Systems. An antibody to 
human type-I collagen was obtained from Chemicon 
International. FITC-conjugated anti-rabbit IgG, 
alkaline phosphatase-conjugated anti-rabbit IgG and 
horseradish peroxidase-conjugated anti-goat IgG 
antibodies were purchased from Bio-Rad. Alexa 
Fluor® 568-labeled donkey anti-goat IgG antibody 
was purchased from Molecular Probes. A Cellular 
Activation of Signaling ELISA CASETM Kit for ERK1/2 
T202/Y204 was purchased from SuperArray 
Bioscience, and a Procollagen type-I C-terminal 
peptide EIA kit was purchased from Takara Bio 
(Japan). A Human 1A Oligo Microarray Kit was 
purchased from Agilent Technologies. Other 
chemicals were obtained from Wako Pure Chemicals 
(Japan). 
Isolation of HDPCs 
Human dental pulp cells (HDPCs) were derived 
from the detached primary tooth of an 8-year-old boy. 
Cells in the dental pulp were removed and transferred 
into type-I collagen-coated 12-well cell culture plates 
and then cultured in α -MEM supplemented with 10% 
FBS and antibiotics [a mixture of 50 μg/ml kanamycin, 
10 μg/ml tetracycline, 100 μg/ml ampicillin and 100 
ng/ml fungisone (amphotericin B)], at 37˚C in a 
humidified atmosphere of 5% CO2 in air. The medium 
was changed every day, and when the cells had 
become confluent, they were trypsinized and seeded 
into a 60-mm culture dish. HDPCs were subsequently 
maintained in α-MEM supplemented with 10% FBS at 
37˚C in a humidified atmosphere of 5% CO2 in air. 
Characterization of HDPCs 
For chondrogenic differentiation, pelleted 
HDPCs (2.5x105 cells/each) were cultured in a 15-mL 
conical tube, and the cells were treated with a 
chondrogenic cocktail containing dexamethasone, 
ascorbate-phosphate, proline, pyruvate and TGF-β3, 
all supplied with the hMSC-FI kit. After 24 days of 
treatment with the chondrogenic cocktail, the cell 
pellet was fixed using 4% paraformaldehyde in PBS 
and sectioned using standard cryosectioning methods. 
For adipogenic differentiation, HDPCs (2x104 
cells/well) were cultured on a Lab-Tek® 
Chamber-SlideTM system (Nunc). The cells were 
treated for 30 days with the adipogenic cocktail, 
containing hydrocortisone, isobutylmethylxanthine 
and indomethacin, supplied with the hMSC-IF kit. 
Differentiation of HDPCs into chondrocytes was 
determined in the cryosectioned sample by 
immunohistochemical methods for detecting aggrecan 
using goat anti-aggrecan antibody and Alexa Fluor® 
568-labeled donkey anti-goat IgG antibody. 
Hematoxylin-eosin (HE) staining was also performed 
using a standard protocol. To confirm the 
differentiation into chondrocytes, alcian blue staining 
was also performed, as previously described [23]. 
Cell proliferation assay 
HDPCs were seeded on 96-well cell culture 
plates at a density of 4,000 cells/well and maintained 
in  α-MEM supplemented with 10% FBS. After 
incubation for 24 hours, the medium was replaced 
with serum-free α-MEM, and the cells were further 
incubated for 24 hours prior to the addition of 0.2 ~ 1 
mM of poly(P), which is an optimal concentration Int. J. Biol. Sci. 2008, 4 
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range for cell proliferation. Cell proliferation after 21 
hours and 45 hours of cultivation was determined 
using a CellTiter 96® AQueous One Solution Cell 
Proliferation Assay Kit (Promega).   
Detection of intracellular and cell surface 
receptor-bound FGF-2 
HDPCs were plated on a 100-mm culture dish at 
a density of 5x105 cells/dish and maintained in 
α-MEM supplemented with 10% FBS (growth 
medium). After the cells had become confluent, they 
were washed with serum-free α-MEM to remove any 
residual FGF-2 from the growth medium. After 
washing the cells, the medium was replaced with 
serum-free  α-MEM, and the cells were further 
incubated for 12 hours. 
To analyze the production and stability of FGF-2, 
intracellular FGF-2 and cell surface receptor-bound 
FGF-2 were quantified as follows. After 12 hours of 
incubation with serum-free α-MEM, both FGF-2 
located at the cell surface (cell surface receptor-bound 
FGF-2) and intracellular FGF-2 were collected. Cell 
surface receptor-bound FGF-2 was collected as 
previously described [8, 24]. After removing 
receptor-bound FGF-2, the remaining cells were 
washed twice with PBS before the cells were scraped. 
Scraped cells were collected and suspended in 20 mM 
Tris-HCl (pH 7.5) and ultrasonicated on ice, and the 
protein concentration was measured using a BCA 
protein assay kit (PIERCE). The amounts of FGF-2 
located both at the cell surface and inside the cells 
(self-produced FGF-2) were estimated by Western 
blotting [25]. 
The stability of FGF-2 bound to its cell surface 
receptor was also examined. After HDPCs had 
become confluent, the cells were incubated with 
serum-free  α-MEM containing purified human 
recombinant FGF-2 at a final concentration of 40 
ng/ml in the presence or absence of poly(P) (1 mM). 
After 20 and 40 hours of incubation, cell surface 
receptor-bound FGF-2 was collected as previously 
described [8]. The amount of FGF-2 was estimated by 
Western blotting. 
Determination of ERK1/2 phosphorylation level in 
HDPCs 
HDPCs were seeded on 96-well plates at a 
density of 2,000 cells/well. After 24 hours of 
incubation, the culture medium was replaced with 
serum-free  α-MEM, and the cells were further 
incubated for 18 hours prior to poly(P) treatment. The 
cells were then treated with serum-free α-MEM 
containing poly(P) (0.2 mM or 1 mM) or human 
recombinant FGF-2 (12.5 ng/ml) for 24 or 48 hours. 
The phosphorylation level of intracellular ERK1/2 
was determined using the Cellular Activation of 
Signaling ELISA CASETM Kit for ERK1/2 T202/Y204, 
following the manufacturer’s instructions. The total 
amounts of ERK1/2 and phosphorylated ERK1/2 
were estimated by this ELISA kit using anti-ERK1/2 
and anti-phosphorylated ERK1/2 antibodies, 
respectively. 
Induction of cell calcification 
In order to estimate the level of collagen 
expression, mRNA expression determined both by 
RT-PCR and microarray analyses, and calcium 
deposition, cells were cultured as follows. HDPCs and 
hMSCs were plated on 60-mm culture dishes at a 
density of 1x105 cells/dish and maintained in their 
respective growth media. For alizarin red staining, 
cells were plated on 12-well cell culture plates at a 
density of 1x104 cells/well. After the cells had become 
confluent, the medium was replaced with α-MEM 
supplemented with 1% FBS. Poly(P) (1 mM) was 
added to the culture media if necessary, and the cells 
were further incubated. The culture medium, which 
was supplemented with poly(P) or not supplemented 
with poly(P), was replaced every fourth day. 
Detection of type-I collagen and quantification of its 
C-terminal peptide 
Expression levels of type-I collagen in HDPCs 
and hMSCs after 5 days of treatment were analyzed 
and quantified by immunostaining. The method for 
the induction of cell differentiation is described above. 
After 5 days of incubation, cells were fixed with 
phosphate-buffered formaldehyde and the expression 
of type-I collagen was detected by 
immunohistochemical methods using an FITC-labeled 
secondary antibody. Nuclei were stained with 10 
ng/mL 4',6-Diamidino-2-phenylindole (DAPI). Each 
fluorescent image of type-I collagen (visualized using 
FITC) and nuclei (DAPI) was captured and analyzed 
using a fluorescent microscope and an image analysis 
system (Leica Microsystems). Relative type-I collagen 
expression levels were calculated by dividing the FITC 
fluorescence intensity by the number of cells (nuclei). 
The relative fluorescent intensity is presented as the 
average value of 3 areas of each treatment group. 
  The secretion level of the type-I collagen 
C-terminal peptide (PIP) in the cell culture 
supernatant was estimated as follows. HDPCs were 
seeded on 96-well plates at a density of 2,000 
cells/well, and cell differentiation was induced as 
described above. For each culture, the medium was 
collected every fourth day, and the total amount of 
PIP in the culture medium was determined using the 
procollagen type-I C-terminal peptide EIA kit, 
following the manufacturer’s instructions. Int. J. Biol. Sci. 2008, 4 
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Quantification of mRNA levels by real-time PCR 
Total RNA was obtained using an SV Total RNA 
Isolation System (Promega), following the 
manufacturer’s instructions. Reverse transcription 
reactions were performed using an oligo dT (20-mer) 
primer and ReverTra AceTM (TOYOBO) for 30 minutes 
at 42˚C. The synthesized cDNAs were used for 
quantitative PCR analysis with specific primers 
designed to hybridize to the exon/ intron junctions. 
Quantification of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA (as an internal 
control for gene expression in the cells) was 
performed using TaqMan® Human GAPDH Control 
Reagents (with VICTM Probe, Applied Biosystems). 
The expression of matrix metalloproteinase-1 (MMP-1) 
mRNA was detected using SYBR® Green. Detection of 
osteopontin (OPN) and osteocalcin (OC) mRNAs was 
performed using TaqMan® FAM-MGB probes. The 
sequences of the designed primers for detection of 
MMP1, OPN and OC and the sequences of the 
TaqMan® FAM-MGB probes for OPN and OC are 
shown in the legend of Figure 5. Quantitative PCR 
analysis was performed using an ABI Prism 7000 
Sequence Detection System and TaqMan® Universal 
PCR Master Mix for detection of OPN and OC mRNA 
and using SYBR® Green PCR Master Mix for 
detection of MMP-1 mRNA (both provided by 
Applied Biosystems) with 40 cycles of 95˚C for 15 
seconds and 60˚C for 1 minute, following the 
manufacturer’s protocol. Each mRNA expression level 
was normalized by the expression level of GAPDH, 
and the relative expression level of each gene is shown 
as a relative value when the expression level of day 0 
was set at 1. 
Microarray analyses 
Total RNA of poly(P)-treated and non-treated 
cells was purified from both HDPCs and hMSCs at 21 
days after treatment using an SV Total RNA Isolation 
System (Promega) according to the manufacturer’s 
instructions. Each 500 μg of isolated total RNA was 
used to amplify and synthesize cRNA, and each 0.75 
μg of synthesized cRNA probes from non-treated cells 
and that from poly(P)-treated cells were labeled with 
cyanine 3-labeled CTP and cyanine 5-labeled CTP, 
respectively. Then gene expressions were analyzed by 
hybridizing the labeled cRNA probes to a human 1A 
oligonucleotide microarray version 2, which contains 
18,716 known human genes. The array was scanned 
by an Agilent dual-laser DNA microarray scanner, 
and the data were extracted by Feature Extraction 
software (Agilent Technologies). 
Alizarin red staining 
Following the method for the induction of cell 
differentiation described above, HDPCs and hMSCs 
were treated with 1 mM of poly(P) for 34 days and 24 
days, respectively. The cells were washed once with 
PBS and fixed with phosphate-buffered formalin for 
20 min. Fixed cells were washed once with distilled 
water and subsequently stained with 1% alizarin red S 
dissolved in distilled water for 5 min. The remaining 
dye was washed out with distilled water, and the cells 
w e r e  w a s h e d  o n c e  m o r e .  F i n a l l y ,  t h e  c e l l s  w e r e  
air-dried and images of the stained cells were 
captured using a light microscope and its image 
analyzing software (Leica). 
3.  Results 
Characterization of HDPCs derived from human 
dental pulp 
In order to confirm that HDPCs isolated from 
human dental pulp contain multipotent MSCs, the 
cells were treated with both the chondrogenic cocktail 
and the adipogenic cocktail (see Materials and Methods) 
to induce cell differentiation into chondrocytes and 
adipocytes, respectively. After 24 days of treatment 
with the chondrogenic cocktail, HDPCs were stained 
with both alcian blue (Fig. 1A) and anti-aggrecan 
antibody (Fig. 1B), indicating that the cells had 
differentiated into chondrocytes. Hypertrophic cells, 
which correspond to differentiated chondrocytes, 
were also observed at the peripheral area of the cell 
pellet (Fig. 1C). In addition, some populations of 
HDPCs produced lipid particles after 30 days of 
treatment with the adipogenic cocktail described 
above (Fig. 1D and 1E). These results suggest that 
HDPCs have multipotent ability to differentiate into 
both chondrocytes and adipocytes. These findings are 
consistent with the results of previous studies 
showing the existence of multipotent mesenchymal 
stem cells (MSCs) in human dental pulp that have the 
potential to differentiate into adipocytes [21, 22]. Also, 
we have found that human dental pulp cells have the 
ability to differentiate into chondrocytes. Based on 
these results, we decided to use HDPCs in this study 
as our MSC-containing population of primary culture 
cells.  
Enhancement of proliferation of HDPCs by poly(P) 
Since cell proliferation is one of the important 
steps for the initial phase of bone generation, we first 
investigated the effect of poly(P) on the proliferation 
of HDPCs. The addition of 1 mM poly(P) to the cell 
culture medium enhanced the proliferation of HDPCs 
up to 1.24 fold and 1.74 fold of that of non-treated cells 
after 21 and 45 hours of incubation, respectively (Fig. 
2A). 
Since it has been reported that poly(P) enhances 
the proliferation of fibroblasts by facilitating the Int. J. Biol. Sci. 2008, 4 
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autocrine functions of FGF-2 [8], we also confirmed 
the existence of FGF-2 on the cell surface as well as the 
presence of intracellular FGF-2 expressed in HDPCs. 
Both intracellular FGF-2 (Fig. 2B, lane 2) and cell 
surface receptor-bound FGF-2 (Fig. 2B, lane 3) were 
detected in HDPCs. Poly(P) could stabilize 
self-produced FGF-2, resulting in the enhancement of 
proliferation of HDPCs. 
Furthermore, the stability of FGF-2 located at the 
cell surface receptors was also examined by adding 
purified FGF-2 (40 ng/ml) to the cell 
culture medium. FGF-2 was stably 
maintained at the cell surface in the presence of 
poly(P) for more than 40 hours (Fig. 2C, lane 5), 
whereas little FGF-2 was detected without poly(P) at 
the cell surface after 20 hours of incubation (Fig. 2C, 
lane 2). No FGF-2 was observed after 40 hours of 
incubation without poly(P) (Fig. 2C, lane 4). From 
these results, the mechanism for proliferation of the 
HDPCs could be explained as the result of the 
enhancement of FGF-2 functions by poly(P). 
 
Fig. 1. Multipotentiality of HDPCs isolated 
from human dental pulp. Isolated HDPCs 
were differentiated into chondrocytes (A, 
B, C) and adipocytes (D, E) under 
appropriate conditions described in 
Materials and Methods. (A) Differentiated 
chondrocytes were stained with alcian blue, 
and (B) the expression of aggrecan (a 
chondrocyte marker) was visualized by 
immunostaining. (C) Cell morphology of 
the differentiated chondrocyte was 
visualized by HE staining. Hypertrophic 
cells were observed at the peripheral area 
of the cell pellet. (D) Cell morphology of 
the differentiated adipocyte and (E) its high 
magnified image. Lipid accumulation was 
observed in the differentiated cells. Bars: 50 μm scale.   
 
 
Fig. 2. Enhancement of self-produced 
(autocrine) FGF function and the resultant 
proliferation of HDPCs by poly(P). (A) Cell 
proliferation after 21 and 45 hours of 
treatment with or without 1 mM poly(P) was 
measured by the MTS method. Relative cell 
growth was estimated by the absorbance of 
non-treated cells after 21 hours of 
incubation, which was set at 1. Open bars, 
relative cell growth of non-treated cells; gray 
bars, relative cell growth of poly(P)-treated 
(1 mM) cells. Significant differences 
between the relative cell growth rate for 
poly(P)-treated cells and the control cells 
were determined by Student’s t test. Asterisk 
(*), p <0.01 to control (none). (B) Expression 
and localization of self-produced (autocrine) FGF-2 in HDPCs. Intracellular FGF-2 and cell surface receptor-bound FGF-2 were 
analyzed by Western blotting. Lane 1, purified recombinant human FGF-2 standard (10 ng loaded); lane 2, intracellular FGF-2 in 
HDPCs; lane 3, receptor-bound FGF-2 of HDPCs. (C) Stabilization of FGF-2 located at cell surface receptors. Purified FGF-2 (40 
ng/ml) was added to the cell culture medium and incubated for 20 or 40 hours. Cell surface receptor-bound FGF-2 was eluted by 
the method described in Materials and Methods. The amount of extracted FGF-2 was estimated by Western blotting. Lane 1, 
purified recombinant human FGF-2 standard (10ng loaded); lane 2, receptor-bound FGF-2 of non-treated cells (20 hours after 
addition of FGF-2); lane 3, receptor-bound FGF-2 of poly(P)-treated cells (20 hours after addition of FGF-2); lane 4, 
receptor-bound FGF-2 of non-treated cells (40 hours after addition of FGF-2); lane 5, receptor-bound FGF-2 of poly(P)-treated 
cells (40 hours after addition of FGF-2). 
B
FGF-2
123
C
12345
FGF-2
A
0
0.5
1
1.5
2
21 45
Time (hours)
R
e
l
a
t
i
v
e
 
c
e
l
l
 
g
r
o
w
t
h
 
(
f
o
l
d
s
) None
Poly(P)
*
* B
FGF-2
123 B
FGF-2
123
FGF-2 FGF-2
123
C
12345
FGF-2
C
12345
FGF-2
12345
FGF-2 FGF-2
A
0
0.5
1
1.5
2
21 45
Time (hours)
R
e
l
a
t
i
v
e
 
c
e
l
l
 
g
r
o
w
t
h
 
(
f
o
l
d
s
) None
Poly(P)
*
* A
0
0.5
1
1.5
2
21 45
Time (hours)
R
e
l
a
t
i
v
e
 
c
e
l
l
 
g
r
o
w
t
h
 
(
f
o
l
d
s
) None
Poly(P)
None
Poly(P)
*
*Int. J. Biol. Sci. 2008, 4 
 
42
Enhancement of ERK1/2 phosphorylation by 
poly(P) 
To confirm whether FGF-2 that is stabilized by 
poly(P) and located at the cell surface receptor is 
physiologically active, the phosphorylation level of 
mitogen-activated protein kinase (MAPK) ERK1/2, 
which is involved in the FGF-induced cell signaling 
pathway [26], was evaluated in the presence and 
absence of poly(P). As shown in Fig. 3, ERK1/2 
phosphorylation in poly(P)-treated HDPCs was 
slightly enhanced after 24 hours (1.3- and 1.2-times 
enhanced in 0.2 and 1 mM poly(P)-treated cells, 
respectively, compared to that in non-treated cells), 
while the enhancement in FGF-2-treated cells was 
about 2.2-times greater than that in non-treated cells. 
However, after 48 hours, the phosphorylation level in 
poly(P)-treated (0.2 mM) cells was further increased to 
the almost same level as that of FGF-2-treated cells 
(1.7-times greater than that in non-treated cells). In 1 
mM poly(P)-treated cells, ERK1/2 phosphorylation 
was also enhanced by about 1.5-times compared to 
that in non-treated cells after 48 hours of incubation. 
These results suggest that poly(P) activates the 
FGF-mediated cell signaling pathway by stabilizing 
FGF-2 bound at the cell surface receptors. 
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Fig. 3. Elevated phosphorylation level of ERK1/2 in HDPCs 
treated with poly(P). Phosphorylation levels of ERK1/2 after 
poly(P) treatment were estimated by ELISA. Relative 
phosphorylation levels of ERK1/2 were estimated by dividing 
the amount of phosphorylated ERK1/2 by the total amount of 
ERK1/2. Open bars, relative phosphorylation level of ERK1/2 
in non-treated cells; closed bars, level in 10 ng/ml 
FGF-2-treated cells; shaded bars, level in 0.2 mM 
poly(P)-treated cells; gray bars, level in 1 mM poly(P)-treated 
cells. Each value is the average of three independent assays. 
Significant differences between the values of poly(P)-treated 
cells and the control cells (None) were determined by Student’s 
t test. Asterisk (*), p <0.01 to control (none). 
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Fig. 4. Production and maturation of type I collagen. Type-I collagen expression in HDPCs (A) and hMSCs (B). Cells were treated 
with or without poly(P) for 5 days, and the expression of type-I collagen was detected by immunostaining as described in 
Materials and Methods. Open bars, relative expression level of type-I collagen in non-treated cells; gray bars, level in 1 mM 
poly(P)-treated cells. Significant differences between the values of the poly(P)-treated group [Poly(P)] and the control group 
(None) were determined by Student’s t test. Asterisk (*), p <0.01 to the control (none). (C) Expression levels of PIP in cell culture 
supernatants. The concentration of PIP released from HDPCs was determined by ELISA. Open circles, PIP released from cells that 
were not subjected to any treatment; closed squares, PIP released fromcells that were treated with 1 mM poly(P). Each value is the 
average ± SD of three independent experiments. Significant differences between two values (Poly(P) and None) at the same time 
point were determined by Student’s t test. Asterisk (*), p <0.01 to control (none). Double asterisk (**), p <0.05 to control (none). 
 
Acceleration of both expression and maturation of 
type-I collagen by poly(P) 
During cell calcification, extracellular matrix 
formation is followed by cell proliferation. The 
extracellular matrices consist primarily of type-I colla-
gen, the production of which is induced during bone 
differentiation [27]. HDPCs treated with poly(P) for 5 
days expressed a larger amount of type-I collagen Int. J. Biol. Sci. 2008, 4 
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than did non-treated cells (Fig. 4A). The estimated 
expression level of type-I collagen was significantly 
increased in poly(P)-treated cells, being 1.7-fold higher 
than that in non-treated cells. Similarly, type-I 
collagen expression was also greatly enhanced by 
poly(P) in hMSCs, the level being1.2-fold higher than 
that in non-treated cells (Fig. 4B). 
Since evaluation of collagen production by im-
munofluorescence is not sufficient as a quantitative 
analysis, more accurate analysis was performed by 
measuring PIP level using ELISA. The level of PIP 
released from HDPCs into the medium was also meas-
ured. PIP is used as a clinical index for bone turnover 
[28] since it is released into blood when type-I collagen 
has matured. Higher PIP levels indicate a higher 
maturation level of collagen from pro-collagen 
molecules. Also, higher production levels of collagen 
are achieved with poly(P) treatment. The high level of 
PIP release from HDPCs was maintained in the 
poly(P)-treated group, whereas the level of PIP release 
in non-treated cells gradually decreased as the 
treatment time increased (Fig. 4C). These results indi-
cated that poly(P) continuously accelerated the 
production and maturation of the extracellular matrix 
in both cell types. 
Microarray analysis of 
bone-related genes in-
duced by poly(P) 
To examine the ef-
fect of poly(P) on general 
gene expression, espe-
cially the expression of 
bone-related genes, the 
m R N A  l e v e l s  o f  b o t h  
HDPCs and hMSCs 
treated with poly(P) for 
21 days and 23 days 
were compared with the 
mRNA levels of 
non-treated cells by mi-
croarray analysis (Table 
1). The expression levels 
of matrix metallopro-
teinase-1 (MMP-1, inter-
stitial collagenase) in 
HDPCs and hMSCs were 
greatly increased in 
poly(P)-treated cells, 
being 47-fold and 39-fold 
higher than the level in 
control cells, respec-
tively. MMP-1, which is 
a major collagenase that 
catalyzes the degrada-
tion of type-I collagen into gelatin and is therefore in-
volved in collagen turnover, is essential for bone 
remodeling [29]. Together with MMP-1 expression, 
the expressions of OPN and OC in both cell types 
were also induced by poly(P) treatment. A series of 
specific markers are expressed during cell calcifica-
tion. Furthermore, a series of proteins are secreted into 
extracellular matrices and they play important roles in 
osteoblast attachment in extracellular matrices. OPN 
and OC are well-known osteoblast differentiation 
markers [30], and those osteoblast differentiation 
markers were also induced in MSCs during cell 
calcification [19]. The other bone-related genes, whose 
expression levels in poly(P)-treated cells were more 
than 3-fold higher than those in non-treated cells, in-
cluded those encoding type-X collagen (7.3-fold and 
4.9-fold higher levels in HDPCs and hMSCs, respec-
tively) and osteoprotegerin (OPG) (3.33-fold and 
3.11-fold higher levels in HDPCs and hMSCs, respec-
tively). 
Table 1. Bone-related gene expression profile both in HDPC 
and hMSCs. 
 Int. J. Biol. Sci. 2008, 4 
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Real-time PCR analysis of MMP1, OPN and OC 
mRNA levels 
The expression levels of MMP-1, OPN and OC 
mRNA were confirmed by RT-PCR. As shown by 
microarray analysis, the expression of MMP-1 was 
greatly induced by poly(P). The relative expression 
levels were around 200-fold greater in poly(P)-treated 
HDPCs and hMSCs at 21 days and 23 days, 
respectively (Fig. 5A and 5B). As was found for 
MMP1, the expression of OPN mRNA was 
significantly induced by poly(P), and the maximum 
expression levels were about 72-fold higher than those 
in non-treated cells after 21 days of treatment in 
HDPCs (Fig. 5C). The expression of OC 
mRNA in HDPCs was also greatly 
induced by poly(P) (Fig.5E). Similarly, 
both OPN and OC expression levels were 
significantly increased in hMSCs by 
poly(P) after 23 days of treatment (Fig. 5D and 5F). 
Induction of cell calcification by poly(P) 
To visualize calcium deposition and cell 
calcification, both HDPCs and hMSCs were stained by 
alizarin red. As shown in Fig. 6, HDPCs and hMSCs 
treated with poly(P) showed visible calcium 
deposition after the addition of poly(P), whereas no 
calcification was observed in non-treated cells. The 
level of calcium deposition increased at 20 and 17 days 
after poly(P) treatment in HDPCs and hMSCs, 
respectively. Calcification reached a maximum level at 
around 34 to 24 days after the start of poly(P) 
treatment in HDPCs and hMSCs, respectively.   
 
 
Fig. 5. Changes in the relative mRNA levels of 
MMP-1, OPN and OC genes during poly(P) 
treatment. The mRNA levels of MMP-1 (A and 
B), OPN (C and D) and OC (E and F) in HDPCs 
(A, C and E) and hMSCs (B, D and F) were 
determined by quantitative real-time PCR using 
an ABI Prism 7000 Sequence Detection System. 
The sequences of the designed primers are 
5’-CATCCAAGCCATATATGGACGTTCCC-3
’ and 
5’-AGAACATCACTTCTCCCCGAATCGTAG-
3’ for MMP-1, 5’-CCCTGGCTGCGCTCTGT-3’ 
and 5’-GCGCCGGAGTCTGTTCAC-3’ for OC 
and 5’-ACTTTCACTCCAATCGTCCCTACA 
-3’ and 
5’-GGCATCAGGATACTGTTCATCAGA -3’ 
for OPN, and the sequences of TaqMan® 
FAM-MGB probes are 
5’-FAM-CTGACAAAGCCTTCATGTC-MGB-
3’ for OC and 
5’-FAM-TCAAAGTCTAGGAGTTTCC-MGB-
3’ for OPN. The basic procedures used for 
quantitative PCR are described in Materials and 
Methods. Open bars, relative gene expression 
levels in non-treated cells; gray bars, levels in 1 
mM poly(P)-treated cells. Relative expression 
levels of each genes were calculated when the 
expression level of day 0 was set at 1. Each value 
is the average ± SD of three independent 
experiments. Significant differences between the 
values of the poly(P)-treated group and control 
group (none) at the same time points (days) were 
determined by Student’s t test. Asterisk (*),  p 
<0.01 to control (none). Double asterisk (**), p 
<0.05 to control (none). 
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Fig. 6. Acceleration of cell calcification by poly(P). Time 
course of calcification in HDPCs and hMSCs during poly(P) 
treatment. HDPCs and hMSCs were treated with 1 mM poly(P) 
for 34 and 24 days, respectively. Non-treated HDPCs and 
hMSCs (None) cultured for 34 and 24 days, respectively, were 
also stained with alizarin red. 
 
4.  Discussion 
HDPCs isolated from human dental pulp show 
multipotent ability to differentiate into chondrocytes 
and adipocytes under appropriate conditions. 
Previous studies demonstrated that dental pulp 
contained multipotent MSCs that could differentiate 
into odontoblasts, adipocytes and neuronal cells [21, 
22]. Our results have further shown that human dental 
pulp cells have the potential to differentiate into 
chondrocytes. This result also indicates that human 
dental pulp cells have the characteristics of MSCs. 
Although the growth of HDPCs almost stopped 
in serum-free culture medium (doubling time of 64.5 
hours), the mitogenic activity of HDPCs was enhanced 
by the addition of poly(P), increasing to a doubling 
time of 21.5 hours. Thus, poly(P) dramatically 
enhances cell proliferation in the absence of serum by 
accelerating cell division. Since HDPCs themselves 
express and secrete FGF-2, and since the secreted 
FGF-2 was found to be stably maintained at the cell 
surface for more than 40 hours in the presence of 
poly(P), the enhancement of HDP cell proliferation by 
poly(P) could result from this stabilizing effect of 
poly(P) on self-produced FGF-2. Our unpublished 
data also showed that purified FGF-2 added to culture 
media was stably maintained on the cell surface for up 
to 5 days. This is consistent with the results of our 
previous study showing enhancement of fibroblast 
proliferation by poly(P), which stabilizes FGF-2 
molecules and strengthens the binding affinity 
between FGF-2 and its cell surface receptors [8]. With 
regard to the mechanism of growth stimulation by 
poly(P), a similar effect has also been reported by 
adding heparin to culture media. Heparin and 
heparin-like glycosaminoglycans are well-known 
potent modulators of FGF-1 and FGF-2, and they 
potentiate the mitogenic activity of both FGFs [31, 32]. 
Heparin sulfate stabilizes FGFs and binds to a site on 
the receptor and at least one site on the growth factor. 
Poly(P) may also facilitate FGF-2 binding to its 
receptors and promote signaling through the same 
binding sites as those of heparin sulfate, FGF-2 and its 
receptors since both molecules are negatively charged 
cellular polymers. 
Phosphorylation of MAPK ERK1/2 was also 
induced by poly(P). This means that the FGF signaling 
pathway was activated by receptor-bound FGF-2, 
which was stabilized by poly(P). Since it took more 
than 24 hours for accumulation of self-produced 
FGF-2 that is sufficient to induce the activation of 
ERK1/2, only slight enhancement of the 
phosphorylation of ERK1/2 was observed within 24 
hours; however, strong enhancement was detected 48 
hours after poly(P) treatment (see Fig. 3). Also, there 
was no significant difference between the levels of 
ERK1/2 phosphorylation in 0.2 mM and 1 mM 
poly(P)-treated cells. This is consistent with evidence 
that the level of cell proliferation is almost the same 
when the cells are treated with 0.2 ~ 1 mM poly(P) 
(unpublished results). From these results, we 
concluded that poly(P) stabilizes FGF-2 not only 
physically but also functionally and that it prolongs 
the effect of FGF-2 on the cell. 
Our results also demonstrated that not only the 
proliferation but also the differentiation of HDPCs 
was highly induced by poly(P). Formation of type-I 
collagen, which is the main component of the 
extracellular matrix, both in HDPCs and hMSCs was 
also induced by poly(P). This suggests that the 
differentiation of stem cells was accelerated by 
poly(P), because extracellular matrix formation is a 
crucial step for cell mineralization [27]. In addition, 
the release of PIP from HDPCs was maintained at a 
higher level by poly(P) treatment. Since PIP is released 
during the maturation step of type-I collagen [28], 
poly(P) plays an important role not only in enhancing 
collagen expression but also in accelerating collagen 
maturation. With regard to OPN and OC expression, 
an induction of sequential expression was observed in 
both HDPCs and hMSCs treated with poly(P). We Int. J. Biol. Sci. 2008, 4 
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previously reported that OPN and OC expressions 
were also induced by poly(P) in osteoblast-like 
MC3T3-E1cells, during cell mineralization [9]. Some 
studies have shown that hMSCs expressed these genes 
during mineralization, followed by the differentiation 
into osteoblasts and odontoblasts [21, 22]. This 
indicates that poly(P) is an efficient inducer of 
extracellular matrix formation, which is an initial step 
in cell calcification. 
Microarray analysis showed that both HDPCs 
and hMSCs had a common feature in the expression of 
bone-related genes, including MMP1, OPN, OC, 
collagen type X and OPG, when treated with poly(P). 
The mRNA expression of MMP-1 was greatly induced 
by poly(P), which was reconfirmed by RT-PCR 
analysis. MMP-1 is a major collagenase that catalyzes 
the degradation of type I collagen to gelatin [29]. Since 
FGF-2 induces the expression of MMP-1 [14, 16, 29], 
this elevated mRNA level could have resulted from 
the enhancement of FGF-2 function by poly(P). 
The induced expression of MMP-1 generally 
inhibits extracellular matrix formation [14]. However, 
poly(P) enhances both type-I collagen and MMP-1 
expression, suggesting that the turnover of the 
extracellular matrix could be accelerated by poly(P). 
This is consistent with the acceleration of PIP release 
by poly(P). The accelerated turnover of the 
extracellular matrix may result from feedback 
regulation of accelerated collagen production. 
Expressions of type-X collagen and OPG were 
also induced by poly(P). Type-X collagen is involved 
in skeletal development [33] and facilitates 
endochondral ossification by regulating matrix 
mineralization. OPG negatively regulates osteoclast 
differentiation by inhibiting receptor activation of 
NF-κB [34]. The failure of osteoclast differentiation by 
induced OPG expression results in the inhibition of 
bone absorption. The induced expressions of both 
type-X collagen and OPG could positively regulate 
cell mineralization.   
The induced expression of these bone 
differentiation-related genes by poly(P) suggests that 
various regulatory networks for cell mineralization 
were activated even though these networks partially 
function to negatively regulate bone differentiation as 
a feedback response. Through this active stage, both 
positive and negative responses for cell differentiation 
occurred, and HDPCs and hMSCs could differentiate 
properly. Poly(P) could facilitate the induction of this 
active stage. 
According to an in vivo study, FGF-2 is a potent 
i n d u c e r  o f  b o n e  r e g e n e r a t i o n  a s  w e l l  a s  s o f t  t i s s u e  
regeneration [11-13]. Some in vitro studies have also 
shown that FGF-2 positively contributed to osteoblast 
cell mineralization, although the effect was exclusive 
and dependent on cell differentiation stage [17, 18]. 
Also, both the proliferation and osteogenic 
differentiation of MSCs are induced by FGF-2 [19]. 
Hanada et al. demonstrated that 6-day exposure to 
FGF-2 markedly stimulated cell growth and 
dexamethasone-dependent osteoblastic differentiation 
as shown by OC mRNA expression, bone nodule 
formation, and calcium deposition in MSCs [20]. These 
results are consistent with the findings in this study. It 
has also been reported that the activation of Cbfa1 is 
positively regulated by FGF-2 [35]. Since Cbfa1 is a 
positive regulator for cell calcification, via induction of 
the expression of bone-related genes such as OC, 
osteogenic differentiation and mineralization of MSCs 
were induced by FGF-2 [19, 20]. In the case of 
poly(P)-induced cell differentiation, the stimulation 
level of the FGF signaling pathway on the cells during 
various differentiation stages may be appropriate and 
close to the in vivo level. Since poly(P) only stabilizes 
self-produced (autocrine) FGF and prolongs its 
functions, the negative effect of excess amounts of 
exogenous FGF on cell differentiation may not be 
influenced. Therefore, the in  vitro effect of poly(P) 
closely reflects the in vivo effect of FGF. 
Poly(P) is a widely used material in food 
additives and cosmetics. Since poly(P) is a safe 
material with very low toxicity, it could be easy to 
apply for medical use as a biodegradable material. We 
have confirmed that poly(P) accelerates alveolar bone 
regeneration in rats [36]. These lines of evidence also 
indicate that poly(P) is a promising material for 
inducing dentin regeneration. 
Acknowledgements 
 We thank Ms. A. Mizuno and Dr. K. Ooi for 
their technical assistance and helpful suggestions. This 
work was supported by a Grant-in-Aid for Creation of 
Innovations through the Business-Academic-Public 
Sector Cooperation from the Ministry of Education, 
Culture, Sports, Science and Technology of Japan, and 
a Grant-in-Aid for Development of New Technology 
for Industrial Application from New Energy and 
Industrial Technology Development Organization 
(NEDO). This work was also supported by Research 
Fellowships of the Japan Society for the Promotion of 
Science (JSPS) for Young Scientists (Yumi Kawazoe). 
Conflict of interests 
The authors have declared that no conflict of 
interest exists. 
References 
1.   Kulaev IS. The biochemistry of inorganic polyphosphates. 2nd 
ed. New York: John Wiley & Sons, Inc.; 2004. 
2. Wood HG, Clark JE. Biological aspects of inorganic Int. J. Biol. Sci. 2008, 4 
 
47
polyphosphates. Ann Rev Biochem. 1988; 57: 235-60. 
3.    Kornberg A. Inorganic polyphosphate: toward making a 
forgotten polymer unforgettable. J Bacteriol. 1995; 177: 491-6. 
4.  Kulaev IS, Vogabov VM, Kulakovskaya T. New aspects of 
inorganic polyphosphate metabolism and function. J Biosci 
Bioeng. 1999; 88: 111-29. 
5.    Kumble KD, Kornberg A. Inorganic polyphosphate in 
mammalian cells and tissues. J Biol Chem. 1995; 270: 5818-22. 
6.   Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense 
granules contain polyphosphate and are similar to 
acidocalcisomes of bacteria and unicellular eukaryotes. J Biol 
Chem. 2004; 279: 44250-7. 
7.    Kornberg A, Rao NN and Ault-Riche D. Inorganic 
polyphosphate: a molecule of many functions. Annu Rev 
Biochem. 1999; 68: 89-125. 
8.  Shiba T, Nishimura D, Kawazoe Y, Onodera Y, Tsutsumi K, 
Nakamura R. Modulation of mitogenic activity of fibroblast 
growth factors by inorganic polyphosphate. J Biol Chem. 2003; 
278: 26788-92. 
9.  Kawazoe Y, Shiba T, Nakamura R, Mizuno A, Tsutsumi K, 
Uematsu T, Yamaoka M, Shindoh M, Kohgo T. Induction of 
calcification in MC3T3-E1 cells by inorganic polyphosphate. J 
Dent Res. 2004; 83: 613-8. 
10.   Shiba T, Takahashi Y, Uematsu T, Kawazoe Y, Ooi K, Nasu K, 
Itoh H, Tanaka H, Yamaoka M, Shindoh M, Kohgo T. Effect of 
inorganic polyphosphate on periodontal regeneration. Key Eng 
Mater. 2004; 254-256: 1119-22. 
11. Mayahara H, Ito T, Nagai H, Miyajima H, Tsukuda R, Taketomi 
S, Mizoguchi J, Kato K. In vivo stimulation of endosteal bone 
formation by basic fibroblast growth factor in rats. Growth 
Factors. 1993; 9: 73-80. 
1 2 .  N a k a m u r a  T ,  H a n a d a  K ,  T a m u r a  M ,  S h i b a n u s h i  T ,  N i g i  H ,  
Tagawa M, Fukumoto S, Matsumoto T. Stimulation of endosteal 
bone formation by systemic injections of recombinant basic 
fibroblast growth factor in rats. Endocrinology. 1995; 13: 1276-84. 
13. Zellin G, Linde A. Effects of recombinant human fibroblast 
growth factor-2 on osteogenic cell populations during orthopic 
osteogenesis in vivo. Bone. 2000; 26: 161-8. 
14. Varghese S, Ramsby ML, Jeffrey JJ, Canalis E. Basic fibroblast 
growth factor stimulates expression of interstitial collagenase 
and inhibitors of metalloproteinases in rat bone cells. 
Endocrinology. 1995; 136: 2156-62. 
15. Canalis E, Centrella M, McCarthy T, Effects of basic fibroblast 
growth factor on bone formation in vitro. J Clin Invest. 1988; 81: 
1572-77. 
16. Tang KT, Capparelli C, Stein JL, Stein GS, Lian JB, Huber AC, 
Braverman LE, DeVito LE. Acidic fibroblast growth factor 
inhibits osteoblast differentiation in vitro: altered expression of 
collagenase, cell growth-related, and mineralization-associated 
genes. J Cell Biochem. 1996; 61: 152-66. 
17. Debiais F, Hott M, Graulet AM, Marie PJ. The effects of fibroblast 
growth factor-2 on human neonatal calvaria osteoblastic cells are 
differentiation stage specific. J Bone Miner Res. 1998; 13: 645-54. 
18. Fakhry A, Ratisoontorn C, Vedhachalam C, Salhab I, Koyama E, 
Leboy P, Pacifici M, Kirschner RE, Nah HD. Effects of FGF-2/-9 
in calvarial bone cell cultures: differentiation stage-dependent 
mitogenic effect, inverse regulation of BMP-2 and noggin, and 
enhancement of osteogenic potential. Bone. 2005; 36: 254-66. 
19. Tsutsumi S, Shimazu A, Miyazaki K, Pan H, Koike C, Yoshida E, 
Takagishi K, Kato Y. Retention of multilineage differentiation 
potential of mesenchymal cells during proliferation in response 
to FGF. Biochem Biophys Res Commun. 2001; 288: 413-9. 
20. Hanada K, Dennis JE, Caplan AI. Stimulatory effects of basic 
fibroblast growth factor and bone morphogenetic protein-2 on 
osteogenic differentiation of rat bone marrow-derived 
mesenchymal stem cells. J Bone Miner Res. 1997; 12: 1606-14. 
21. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal 
human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc 
Natl Acad Sci USA. 2000; 97: 13625-30. 
22. Miura M, Grohthos S, Zhao M, Lu B, Fisher LW, Robey PG., Shi S. 
SHED: Stem cells from human exfoliated deciduous teeth. Proc 
Natl Acad Sci USA. 2003; 100: 5807-12. 
23. Asahina I, Sampath TK, Nishimura I, Hauschka PV. Human 
osteogenic protein-1 induces both condroblastic and osteoblastic 
differentiation of osteoprogenitor cells derived from newborn 
rat calvaria. J Cell Biol. 993; 123: 921-33. 
24. Fannon M, Nugent MA. Basic fibroblast growth factor binds its 
receptors, is internalized, and stimulates DNA synthesis in 
Balb/c3T3 cells in the absence of heparin sulfate. J Biol Chem. 
1996; 271: 17949-56. 
25. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A 
Laboratory Manual. Cold Spring Harbor, NY: Cold Spring 
Harbor Laboratory; 1989. 
26. Meloche S, Seuwen K, Pagès G, Pouysseégur J. Biphasic and 
synergistic activation of p44mapk (ERK1) by growth factors: 
correlation between late phase activation and mitogenicity. Mol 
Endo. 1992; 6: 845-54. 
27. Hurley MM, Abreu C, Harrison JR, Lichtler AC, Raisz LG, Kream 
BE. Basic fibroblast growth factor inhibits type I collagen gene 
expression in osteoblastic MC3T3-E1 cells. J Biol Chem. 1993; 
268: 5588-93. 
28. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. 
Radioimmunoassay for the pyridinoline cross-linked 
carboxy-terminal telopeptide of type I collagen: A new serum 
marker of bone collagen degradation. Clin Chem. 1993; 39: 
635-40. 
29. Aho S, Rouda S, Kennedy SH, Qin H, Tan EML. Regulation of 
human interstitial collagenase (matrix metalloproteinase-1) 
promoter activity by fibroblast growth factor. Eur J Biochem. 
1997; 247: 503-10. 
30. Stein GS, Lian JB, Stein JL, Wijnen AJ, Montecino M. 
Transcriptional control of osteoblast growth and differentiation. 
Physiol Rev. 1996; 76: 593-629. 
31. Kwan CP, Venkataraman G, Shriver Z, Raman R, Liu D, Qi Y, 
Varticovski L, Sasisekharan R. Probing fibroblast growth factor 
dimerization and role of heparin-like glycosaminoglycans in 
modulating dimerization and signaling. J Biol Chem. 2001; 276: 
23421-29. 
32. Chua CC, Rahimi N, Forsten-Williams K, Nugent MA. Heparan 
sulfate proteoglycans function as receptors for fibroblast growth 
factor-2 activation of extracellular signal-regulated kinases 1 and 
2. Circ Res. 2004; 94: 316-23. 
33. Gerstenfeld LC, Shapiro FD. Expression of bone-specific genes by 
hypertrophic chondrocytes: Implications of the complex 
functions of the hypertrophic chondrocyte during endochondral 
bone development. J Cell Biochem. 1996; 62: 1-9. 
34. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin 
and its relationship with bone mineral density and markers of 
bone turnover. Osteoporos Int. 2005; 16: 417-23. 
35. Xiao G, Jiang D, Gopalakrishnan R, et al. Fibroblast growth factor 
2 induction of the osteocalcin gene requires MAPK activity and 
phosphorylation of the osteoblast transcription factor, 
Cbfa1/Runx2. J Biol Chem. 2002; 277: 36181-7. 
36. Hacchou Y, Uematsu T, Ueda O, Usui Y, Uematsu S, Takahashi 
M, Uchihashi T, Kawazoe Y, Shiba T, Kurihara S, Yamaoka M, 
Furusawa K. Inorganic polyphosphate: a possible stimulant of 
bone formation. J Dent Res. 2007; 86: 893-7. 
 